The pharmacokinetic study of single and multiple doses of ethyl naphthylidene sulfonate capsules was conducted in healthy subjects to understand the dynamic changes of its absorption, distribution and elimination (metabolism and excretion) in healthy humans.

Start Date-

Sponsor / Collaborator

Jiangsu Yangtze River Pharmaceutical Group Co., Ltd.

[+1]

100 Clinical Results associated with Aclatonium Napadisilate

100 Translational Medicine associated with Aclatonium Napadisilate

100 Patents (Medical) associated with Aclatonium Napadisilate

Literatures (Medical) associated with Aclatonium Napadisilate

01 Jan 2019·LUTS: Lower Urinary Tract SymptomsQ4 · MEDICINE

Effect of combined solifenacin and aclatonium in preventing dry mouth in patients with overactive bladder

Q4 · MEDICINE

Article

Author: Paick, Sung Hyun ; Park, Hyoung Keun ; Yang, Sang‐Kuk ; Yang, Dae Yul ; Chung, Hong ; Kim, Hyeong Gon ; Choi, Woo Suk

ObjectiveThe aim of the present study was to prospectively evaluate the effect of aclatonium on dry mouth in patients with overactive bladder (OAB) after treatment with solifenacin.MethodsA multicenter randomized double‐blind controlled trial was conducted. The study subjects were men and women who had been diagnosed with OAB for ≥3 months and presented with a total Overactive Bladder Symptom Score (OABSS) ≥3. Eligible subjects were randomized to receive 5 mg solifenacin with placebo or 5 mg solifenacin with 150 mg aclatonium once daily for 8 weeks. Subjects rated dry mouth using a visual analog scale (VAS) and completed the OAB‐questionnaire (OAB‐q) short form (SF) and OABSS questionnaires at baseline and after 8 weeks treatment. Dry mouth was defined as a VAS score >30 points (range 0–100).ResultsOverall, 92 patients (49 and 43 in the placebo and aclatonium groups, respectively) completed the 8‐week treatment. In patients who had dry mouth at baseline, no differences were detected in changes in the dry mouth VAS, OABSS, or OAB‐q SF scores between the 2 groups. However, in patients who had no dry mouth at baseline, the change in dry mouth VAS score was significantly lower in the aclatonium‐ than placebo‐treated group: the VAS score increased 20 points in the placebo group compared with 9 points in the aclatonium group (P = .03). However, there were no significant differences in changes in the OABSS and OAB‐q SF scores between the 2 groups.ConclusionsAclatonium decreased dry mouth without disturbing treatment efficacy in patients who did not have dry mouth before treatment.

01 May 2003·EndoscopyQ1 · MEDICINE

Food Residue at Endoscopy in Patients Who Have Previously Undergone Distal Gastrectomy: Risk Factors and Patient Preparation

Q1 · MEDICINE

Article

Author: Adachi, W ; Yazawa, I ; Watanabe, H ; Koide, N

BACKGROUND AND STUDY AIMSFood residue is often seen in the gastric remnant after partial gastrectomy, making it difficult to diagnose early cancer in the residual stomach. The aims of this study were to clarify the risk factors for the accumulation of food residue, and to study methods of preparation for endoscopy in patients who had undergone distal gastrectomy.PATIENTS AND METHODS374 endoscopic examinations of patients who had undergone distal gastrectomy for gastric cancer were compared with 2168 endoscopic examinations in patients without a history of gastrectomy. Relationships between the presence of food residue and a number of clinical factors, including patient preparation, were evaluated by univariate and multivariate analyses.RESULTSFood residue in the gastric remnant was observed in 70 examinations (18.7 %), a significantly higher proportion than that found in control patients (0.3 %). From multivariate analysis, underlying diseases (endocrine, metabolic, or connective tissue disease), Billroth type I reconstruction, and postoperative gastric retention were found to be independent risk factors for the accumulation of food residue. Diet preparation (a liquid diet plus aclatonium napadisilate) significantly decreased the incidence of food residue.CONCLUSIONSOur diet preparation method can be recommended as a preparation for upper gastrointestinal endoscopy in patients who have undergone distal gastrectomy, especially in patients with additional risk factors.

01 Jul 1990·PancreasQ3 · MEDICINE

Action of a New Cholinergic Agonist, Aclatonium Napadisilate, on Isolated Rat Pancreatic Acini

Q3 · MEDICINE

Article

Author: Masatoshi Fujii ; Satoshi Tani ; Yoshinori Okabayashi ; Takashi Fujisawa ; Makoto Otsuki ; Takahiko Nakamura

The effect of aclatonium napadisilate, a newly synthesized choline ester, on pancreatic exocrine function was compared with that of the muscarinic agonist carbamylcholine in isolated rat pancreatic acini. Both compounds increased amylase release and 45Ca2+ efflux in a dose-dependent fashion, and similarly decreased the binding of [N-methyl-3H]scopolamine to isolated rat pancreatic acini. While aclatonium napadisilate was 20-30 times less potent than carbamylcholine in stimulations of amylase release and 45Ca2+ efflux, the potency of aclatonium napadisilate in inhibiting [N-methyl-3H]scopolamine binding was nearly the same as that of carbamylcholine. These results indicate that aclatonium napadisilate stimulates pancreatic exocrine secretion via muscarinic receptors and Ca2+ mobilization, and its intrinsic activity is less than carbamylcholine in the isolated rat pancreatic acini. Since aclatonium napadisilate is known to increase motility and peristalsis of the gastrointestinal tract, stimulatory effects of aclatonium napadisilate, shown in the present study, on digestive enzyme secretion from the pancreas may provide additional benefit of aclatonium napadisilate in the treatment of various gastrointestinal disorders.

100 Deals associated with Aclatonium Napadisilate

External Link

KEGG	Wiki	ATC	Drug Bank
D01955	-	A03FA	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Gastrointestinal motility disorder	JP	FUJIFILM Toyama Chemical Co., Ltd.	01 Jan 1981

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Biliary Dyskinesia	Phase 1	CN	Jiangsu Yangtze River Pharmaceutical Group Co., Ltd.	22 Dec 2017
Feeding and Eating Disorders	Phase 1	CN	Jiangsu Yangtze River Pharmaceutical Group Co., Ltd.	22 Dec 2017
Gastritis	Phase 1	CN	Jiangsu Yangtze River Pharmaceutical Group Co., Ltd.	22 Dec 2017
Nausea	Phase 1	CN	Jiangsu Yangtze River Pharmaceutical Group Co., Ltd.	22 Dec 2017
Vomiting	Phase 1	CN	Jiangsu Yangtze River Pharmaceutical Group Co., Ltd.	22 Dec 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


1960 (AUA2011)	Not Applicable	Urinary Bladder, Overactive	92	Solifenacin 5mg	gaufeqlrrp(svrhfaxcul) = oothqgifff pqvzyuxcky (njbhczbrgr )	-	01 Apr 2011
				Solifenacin 5mg + Aclatonium Napadisilate 150mg	gaufeqlrrp(svrhfaxcul) = ssihujaakl pqvzyuxcky (njbhczbrgr )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Aclatonium Napadisilate

Overview

Basic Info

Structure

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation